NCT03319420View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

January 1, 2021

Study Completion Date

January 1, 2021

Conditions

Dry Eye Due to Sjögren's Syndrome

Interventions

DRUG

LO2A eye drops

Sodium hyaluronate

DRUG

Systane Ultra UD

Active Ingredients; Polyethylene Glycol Propylene Glycol

Trial Locations (5)

Unknown

HaEmek MC, Afula

Rambam, Haifa

Rabin MC, Petah Tikva

Kaplan MC, Rehovot

Ichilov medical center Tel Aviv, Tel Aviv

All Listed Sponsors

lead

Ocuwize LTD

INDUSTRY

NCT03319420 - Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome | Biotech Hunter | Biotech Hunter